4D Molecular Therapeutics (NASDAQ:FDMT) Issues Earnings Results

4D Molecular Therapeutics (NASDAQ:FDMT) announced its quarterly earnings results on Friday. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.10), Zacks reports.

4D Molecular Therapeutics Trading Up 1.1 %

Shares of NASDAQ FDMT traded up $0.05 during midday trading on Friday, hitting $4.53. 1,233,187 shares of the company’s stock were exchanged, compared to its average volume of 846,836. 4D Molecular Therapeutics has a 12-month low of $4.20 and a 12-month high of $36.25. The company has a market cap of $209.41 million, a price-to-earnings ratio of -1.59 and a beta of 2.81. The business’s fifty day moving average price is $5.22 and its two-hundred day moving average price is $8.59.

Analyst Upgrades and Downgrades

Several research firms have issued reports on FDMT. Royal Bank of Canada decreased their price target on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a research report on Thursday, November 14th. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, February 19th. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Monday, February 10th. BMO Capital Markets lowered shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and cut their price target for the company from $40.00 to $15.00 in a research note on Monday, January 13th. Finally, Chardan Capital cut their price target on shares of 4D Molecular Therapeutics from $39.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, 4D Molecular Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $32.13.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.